Cargando…

Recruitment of naive CD4(+) T cells by the recombinant zoster vaccine correlates with persistent immunity

Herpes zoster (HZ) is a substantial problem for people with decreased cell-mediated immunity, including older adults. The first vaccine approved for HZ prevention, the zoster vaccine live (ZVL), which provided limited and short-lived protection, has been supplanted by the superior recombinant zoster...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laing, Kerry J., Ford, Emily S., Johnson, Michael J., Levin, Myron J., Koelle, David M., Weinberg, Adriana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688978/ https://www.ncbi.nlm.nih.gov/pubmed/37788096 http://dx.doi.org/10.1172/JCI172634

Ejemplares similares

Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines
por: Park, Seong Yeon, et al.
Publicado: (2022)

Incidence of Herpes Zoster and Persistent Post-Zoster Pain in Adults With or Without Diabetes in the United States
por: Suaya, Jose A., et al.
Publicado: (2014)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Varicella-zoster virus proteome-wide T-cell screening demonstrates low prevalence of virus-specific CD8 T-cells in latently infected human trigeminal ganglia
por: van Gent, Michiel, et al.
Publicado: (2023)

Immune Senescence Factors Associated with the Immunogenicity of a Live Attenuated Zoster Vaccine (ZV) in Older Adults
por: Weinberg, Adriana, et al.
Publicado: (2017)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

26. Is There a Correlation Between Reactogenicity and Immune Responses of the Adjuvanted Recombinant Zoster Vaccine (RZV)? A Post-hoc Analysis
por: Callegaro, Andrea, et al.
Publicado: (2021)

Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection
por: Vezys, Vaiva, et al.
Publicado: (2006)

HLA-B*57:01 Complexed to a CD8 T-Cell Epitope from the HSV-2 ICP22 Protein Binds NK and T Cells through KIR3DL1
por: Laing, Kerry J., et al.
Publicado: (2022)

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine
por: Callegaro, Andrea, et al.
Publicado: (2021)

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
por: Bastidas, Adriana, et al.
Publicado: (2019)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

Uveitis reactivation following recombinant zoster vaccination
por: Richards, Paige J., et al.
Publicado: (2021)

Vaccination against herpes zoster in developed countries: State of the evidence
por: Drolet, Mélanie, et al.
Publicado: (2013)

2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)
por: Tovar-Salazar, Adriana, et al.
Publicado: (2018)

2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine
por: Schmader, Kenneth E, et al.
Publicado: (2019)

Cost of Herpes Zoster in Patients With Selected Immune-Compromised Conditions in the United States
por: Li, Qian, et al.
Publicado: (2016)

Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer
por: Su, Shicheng, et al.
Publicado: (2017)

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1
por: Colindres, Romulo, et al.
Publicado: (2019)

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials
por: Colindres, Romulo, et al.
Publicado: (2020)

2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults
por: Schmader, Kenneth E, et al.
Publicado: (2018)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults
por: Schmader, Kenneth E, et al.
Publicado: (2020)

Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes zoster
por: Laing, Kerry J., et al.
Publicado: (2022)

5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies
por: Andrew, Melissa K, et al.
Publicado: (2020)

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
por: Cunningham, Anthony L, et al.
Publicado: (2018)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Safety and Varicella Outcomes in In Utero–Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program
por: Duchon, Jennifer M, et al.
Publicado: (2019)

Recombinant zoster vaccine (Shingrix(®)): a new option for the prevention of herpes zoster and postherpetic neuralgia
por: Singh, Grisuna, et al.
Publicado: (2020)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
por: Schmader, Kenneth E, et al.
Publicado: (2019)

Recombinant varicella zoster virus glycoprotein E antigen vaccine for prevention of herpes zoster and postherpetic neuralgia
Publicado: (2021)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

Public Clonotypes and Convergent Recombination Characterize the Naïve CD8(+) T-Cell Receptor Repertoire of Extremely Preterm Neonates
por: Carey, Alison J., et al.
Publicado: (2017)

Expression of CD39 Is Correlated With HIV DNA Levels in Naïve Tregs in Chronically Infected ART Naïve Patients
por: Song, Jin-Wen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9mk21ahrtf5e0g6jmvkjhcg8sq